Nuveen, LLC Larimar Therapeutics, Inc. Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 174,788 shares of LRMR stock, worth $471,927. This represents 0.0% of its overall portfolio holdings.
Number of Shares
174,788Holding current value
$471,927% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
117Shares Held
64.9MCall Options Held
78.9KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$57.3 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$17.4 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$16.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$12.6 Million7.6% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$9.22 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $117M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...